Chewable tablets have also found application in veterinary medicines. This paper reviews considerations for the formulation of chewable tablets including sensory characteristics, chewability ...

Abbott Laboratories, the manufacturers of ritonavir-boosted lopinavir (Kaletra) announced the development of a new tablet formulation of the protease inhibitor on July 27th at the Third International ...

Actinogen Medical Limited (ASX: ACW) announces that a recent trial designed to confirm therapeutic blood levels of the ...

BeOne Medicines recently announced that the European Commission approved a new film-coated tablet formulation of BRUKINSA (zanubrutinib) for all existing indications, halving the required daily ...

The FDA has approved a new tablet formulation for the protease inhibitor ritonavir in combination with other antiretroviral agents for the treatment of HIV.

Tablets are often the first choice of solid dosage forms for many pharmaceutical companies. On November 16, 2021, the US-based contract service provider, CD Formulation announces that it has started ...

The tablet formulation of Brukinsa is supplied as a 160mg dose, allowing patients the convenience of taking only 2 tablets daily. The Food and Drug Administration (FDA) has approved a new tablet ...

This article describes the formulation of a tablet for a specific purpose, primarily using fractional or full factorial designs. The formulation work generated a matrix that was processed by two ...

The new tablet formulation maintains BRUKINSA’s dosing flexibility by providing patients and prescribers with the option of once- or twice-daily dosing and is designed to simplify management of ...

The European Commission has approved a new film-coated tablet formulation of Sino-American oncology-focused biotech BeOne Medicines’ Brukinsa (zanubrutinib) for all approved indications.

BeOne Medicines Ltd., a global oncology company, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending ...